Stable and inducible expression of human metabotropic glutamate receptor types 2, 5, and 8 was achieved in HEK293 cells using the ecdysone inducible system. Treatment of the respective cell lines with ponasterone A resulted in time and concentration-dependent induction of receptor expression. In all cases, the functional activation of receptorswas determined bymeasuring increases in intracellular calcium. The physiologically G• i-coupled receptors mGluR2 andm GluR8 were successfully coupled to phospholipase Cactivation using the chimeric Gprotein G• q/o. The pharmacological properties of recombinant receptors were characterized and proved to be similar to native receptors. Our data suggest that the ecdysone system has a number of characteristics thatmake itwell suited for expressing mGluRs and that the combined use of this systemand chimeric G proteins allows receptors to be characterized using a rapid and straightforward Ca 2+assay.
Neugebauer V: Metabotropic glutamate receptors—important modulators of nociception and pain behavior. Pain2002;98:1-8.
8.
Fisher K, Lefebvre C, Coderre TJ: Antinociceptive effects following intrathecal pre-treatment with selective metabotropic glutamate receptor compounds in a rat model of neuropathic pain. Pharmacol Biochem Behav2002;6677:1-8.
9.
Sharpe EF, Kingston AE, Lodge D, Monn JA, Headley PM: Systemic pretreatment with a group II mGlu agonist, LY379268, reduces hyperalgesia in vivo. Br J Pharmacol2002;135:1255-1262.
10.
Dolan S, Nolan AM: Behavioural evidence supporting a differential role for spinal group I and II metabotropic glutamate receptors in inflammatory hyperalgesia in sheep. Neuropharmacology2002;43:319-326.
11.
Simmons RMA, Webster AA, Kalra AB, Iyengar S: Group IImGluRreceptor agonists are effective in persistent and neuropathic pain models in rats. Pharmacol Biochem Behav2002;73:419-427.
12.
Klodzinska A, Chojnacka-Wojcik E, Palucha A, Branski P, Popik P, Pilc A: Potential anti-anxiety, anti-addictive effects of LY354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology1999;38:1831-1839.
13.
Linden AM, Johnson BG, Peters SC, Shannon HE, Tian M, Wang Y, et al: Increased anxiety-related behaviour in mice deficient for metabotropic glutamate 8 (mGlu8) receptor. Neuropharmacology2002;43:251-259.
14.
Palucha A, Tatarczynska E, Branski P, Szewczyk B, Wieronska JM, Klak K, et al: Group III mGlu receptor agonists produce anxiolytic and antidepressant-like effects after central administration in rats. Neuropharmacology2004;46:151-159.
15.
Desai MA, Burnett JP, Mayne NG, Schoepp DD: Cloning and expression of a human metabotropic glutamate receptor 1 alpha: enhanced coupling on cotransfectionwith a glutamate transporter. Mol Pharmacol1995;48:648-657.
16.
No D, Yao T-P, Evans RM: Ecdysone-inducible gene expression in mammalian cells and transgenicmice. Proc Natl Acad Sci USA1996;93:3346-3351.
17.
Conklin BR, Farfei Z, Lustig KD, Julius D, Bourne HR: Substitution of three amino acids switches receptor specificity of G•q to that of G•i. Nature1993;363:274-276.
18.
Minakami R, Katsuki F, Sugiyama H: Avariant of metabotropic glutamate receptor subtype 5: an evolutionally conserved insertion with no termination codon. Biochem Biophys Res Commun1993;194:622-627.
19.
Wu S, Wright RA, Rockey PK, Burgett SG, Arnold JS, Rosteck PR, et al: Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells. Mol Brain Res1998;53:88-97.
20.
Kowal D, Hsiao C, Ge A, Wardwell-Swanson J, Ghosh K, Tasse R: A 35SGTP.S binding assessment of metabotropic glutamate receptor standards in Chinese hamster ovary cell lines expressing the human metabotropic receptor subtypes 2 and 4. Neuropharmacology1998;37:179-187.
21.
Zhang J-H, Chung TDY, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. JBiomol Screen1999;4:67-73.
22.
Balazs R, Miller S, Romano C, de Vries A, Chun Y, Cotman CW: Metabotropic glutamate receptor mGluR5 in astrocytes: pharmacological properties and agonist potencies. J Neurochem1997;69:151-163.
23.
Daggett LP, Sacaan AI, Akong M, Rao SP, Hess SD, Liaw C, et al: Molecular and functional characterization of recombinant human glutamate receptor subtype 5. Neuropharmacology1995;34:871-886.
24.
Gomeza J, Mary S, Brabet I, Parmentier M, Restituito S, Bockert J, et al: Coupling ofmetabotropic glutamate receptors 2 and 4 to G•15, G•16 and chimeric G• q/ proteins: characterization of new antagonists. Mol Pharmacol1996;50:923-930.
25.
Parmentier ML, Joly C, Restituito S, Bockaert J, Grau Y, Pin J-P: The G protein-coupling profile of metabotropic glutamate receptors, as determined with exogenous Gproteins, is independent of their ligand recognition domain. Mol Pharmacol1998;53:778-786.
26.
Knoflach F, Woltering T, Adam G, Mutel V, Kemp JA: Pharmacological properties of native metabotropic glutamate receptors in freshly dissociated golgi cells of the rat cerebellum. Neuropharmacology2001;40:163-169.
27.
Flor PJ, Lindauer K, Puttner I, Ruegg D, Lukic S, Knopfel T, et al: Molecular cloning, functional expression and pharmacological characterization of the human metabotropic glutamate receptor type 2. Eur J Neurosci1995;7:622-629.
28.
Thomas NK, Wright RA, Howson PA, Kingston AE, Schoepp DD, Jane DE: (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology2001;40:311-318.
29.
Malherbe P, Kratzeisen C, Lundstrom K, Richards JG, Faull RLM, Mutel V: Cloning and functional expression of alternative spliced variants of the human metabotropic glutamate receptor 8. Brain Res Mol Brain Res1999;67:201-210.
30.
Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, et al: 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGluR5 receptor antagonist. Neuropharmacology1999;38:493-1503.
31.
Litschig S, Gasparini F, Ruegg D, Stoehr N, Flor PJ, Vranesic I, et al: CPCCOEt, a non-competitive mGluR1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol1999;55:453-461.
32.
Knoflach F, Mutel V, Jolidon S, Kew JN, Malherbe P, Vieira E, et al: Positive allosteric modulators ofmetabotropic glutamate 1 receptor: characterization, mechanism of action and binding site. Proc Natl Acad Sci U S A2001;98: 13402-13407.
33.
Schaffhauser H, Rowe BA, Morales M, Chavez-Noriega LE, Yin R, Jachec C, et al: Pharmacological characterization and identification of amino acids involved in the positive modulation ofmetabotropic glutamate receptor subtype 2. Mol Pharmacol2003;64:798-810.
34.
Maj M, Bruno V, Dragic Z, Yamamoto R, Battaglia G, Inderbitzin W, et al: (-)PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanismof action, and neuroprotection. Neuropharmacology2003;45:895-906.
35.
O'Brien JA, Lemaire W, Chen T-B, Chang RSL, Jacobson MA, Ha SN, et al: A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol Pharmacol2003;64:731-740.
36.
Mathiesen JM, Svendsen N, Brauner-Osborne H, Thomsen C, Ramirez MT: Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br JPharmacol2003;138:1026-1030.
37.
Van Craenenbroeck K, Vanhoenacker P, Leysen JE, Haegeman G: Evaluation of the tetracycline and ecdysone-inducible systems for expression of neurotransmitter receptors in mammalian cells. Eur J Neurosci2001;14:968-976.
38.
Senner V, Sotoodeh A, Paulus W: Regulated gene expression in glioma cells: a comparison of three inducible systems. Neurochem Res2001;5:521-524.
39.
Xu Z, Mizuguch H, Mayumi T, Hayakawa T: Regulated gene expression from adenovirus vectors: a systematic comparison of various inducible systems. Gene2003;309:145-151.
